Pulmatrix reports Q2 EPS ($1.59) vs. ($1.04) last year

Reports Q2 revenue $1.6M vs. $1.8M last year. CEO Peter Ludlum commented, “Our focus in Q2 has been to continue our cost saving measures, to complete the transactions with MannKind and to continue the wind down of the Phase 2b study for PUR1900. We believe that this has allowed us to reposition ourselves as a virtual company while continuing to focus on strategic alternatives that leverage the potential of PUR3100 and our iSPERSE technology.”